MENU
+Compare
XFOR
Stock ticker: NASDAQ
AS OF
Jan 17 closing price
Price
$0.51
Change
+$0.05 (+10.87%)
Capitalization
86.57M

XFOR X4 Pharmaceuticals Forecast, Technical & Fundamental Analysis

a biotechnology company which engages in developing human antibodies for treating infectious diseases

Industry Biotechnology
XFOR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I.Advisor
a Summary for XFOR with price predictions
Jan 08, 2025

XFOR in -14.01% downward trend, sliding for three consecutive days on January 08, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where XFOR declined for three days, in of 305 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Stochastic Oscillator may be shifting from an upward trend to a downward trend. In of 51 cases where XFOR's Stochastic Oscillator exited the overbought zone, the price fell further within the following month. The odds of a continued downward trend are .

The Moving Average Convergence Divergence Histogram (MACD) for XFOR turned negative on January 07, 2025. This could be a sign that the stock is set to turn lower in the coming weeks. Traders may want to sell the stock or buy put options. Tickeron's A.I.dvisor looked at 50 similar instances when the indicator turned negative. In of the 50 cases the stock turned lower in the days that followed. This puts the odds of success at .

Bullish Trend Analysis

The Momentum Indicator moved above the 0 level on December 26, 2024. You may want to consider a long position or call options on XFOR as a result. In of 101 past instances where the momentum indicator moved above 0, the stock continued to climb. The odds of a continued upward trend are .

Following a +3 3-day Advance, the price is estimated to grow further. Considering data from situations where XFOR advanced for three days, in of 235 cases, the price rose further within the following month. The odds of a continued upward trend are .

The Aroon Indicator entered an Uptrend today. In of 87 cases where XFOR Aroon's Indicator entered an Uptrend, the price rose further within the following month. The odds of a continued Uptrend are .

Fundamental Analysis (Ratings)

The Tickeron Seasonality Score of (best 1 - 100 worst) indicates that the company is fair valued in the industry. The Tickeron Seasonality score describes the variance of predictable price changes around the same period every calendar year. These changes can be tied to a specific month, quarter, holiday or vacation period, as well as a meteorological or growing season.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.452) is normal, around the industry mean (14.746). P/E Ratio (3.104) is within average values for comparable stocks, (88.252). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.853). XFOR has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.013). P/S Ratio (90.090) is also within normal values, averaging (264.084).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. XFOR’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. XFOR’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.

View a ticker or compare two or three
XFOR
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Ad is loading...
A.I. Advisor
published Earnings

XFOR is expected to report earnings to fall 11.11% to -15 cents per share on March 13

X4 Pharmaceuticals XFOR Stock Earnings Reports
Q4'24
Est.
$-0.16
Q3'24
Missed
by $0.01
Q2'24
Beat
by $0.46
Q1'24
Missed
by $0.12
Q4'23
Beat
by $0.05
The last earnings report on November 13 showed earnings per share of -18 cents, missing the estimate of -17 cents. With 1.68M shares outstanding, the current market capitalization sits at 86.57M.
A.I. Advisor
published General Information

General Information

a biotechnology company which engages in developing human antibodies for treating infectious diseases

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
61 North Beacon Street
Phone
+1 857 529-8300
Employees
93
Web
https://www.x4pharma.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
NVDA137.714.14
+3.10%
NVIDIA Corp
ROIV11.150.26
+2.39%
Roivant Sciences Ltd
EPC33.720.53
+1.60%
Edgewell Personal Care Company
PHAT6.96N/A
N/A
Phathom Pharmaceuticals
KPTI0.66-0.04
-5.47%
Karyopharm Therapeutics

XFOR and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, XFOR has been loosely correlated with SYRS. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if XFOR jumps, then SYRS could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To XFOR
1D Price
Change %
XFOR100%
+10.06%
SYRS - XFOR
48%
Loosely correlated
+7.02%
IMMP - XFOR
36%
Loosely correlated
-0.52%
XCUR - XFOR
34%
Loosely correlated
+13.27%
SPHDF - XFOR
34%
Loosely correlated
N/A
ABSI - XFOR
33%
Loosely correlated
+3.57%
More